enjaymo
sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunosupresivi - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).
rifamor 300mg kapsula, tvrda
"glk pharma" druŠtvo sa ograniČenom odgovornoŠĆu, podgorica - rifampicin - kapsula, tvrda - 300mg
rotateq 2.2x10exp6 i.j./doza + 2.8x10exp6 i.j./doza + 2.2x10exp6 i.j./doza + 2.0x10exp6 i.j./doza + 2.3x10exp6 i.j./doza oralni rastvor
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - vakcina protiv rotavirusa, pentavalentna, živa, reasortirana - oralni rastvor - 2.2x10exp6 i.j./doza + 2.8x10exp6 i.j./doza + 2.2x10exp6 i.j./doza + 2.0x10exp6 i.j./doza + 2.3x10exp6 i.j./doza
priorixtetra 3 log10ccid50/0.5 ml+ 4,4 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml+ 3,3 log10pfu/0.5 ml prašak i rastvarač za rastv
glaxosmithkline d.o.o.sarajevo - kombinovana пропорциональному protiv morbila, parotitisa, rubeole sam varičela, ziva, atenuisana - prašak i rastvarač za rastvor za injekciju u napunjenom injekcionom špricu - 3 log10ccid50/0.5 ml+ 4,4 log10ccid50/0.5 ml+ 3 log10ccid50/0.5 ml+ 3,3 log10pfu/0.5 ml - 0,5 ml rastvora za injekciju sadrži: 3,0 log ccid50 živog atenuisanog virusa morbila (schwarz soj); 4,4 log ccid50 živog atenuisanog virusa parotitisa (rit 4385 soj, dobiven iz soja jeryl lynn)); 3,0 log ccid50 živog atenuisanog virusa rubele (wistar ra 27/3 soj); 3,3 log pfu živog atenuisanog virusa varičela (soj oka)
vaxigriptetra, suspenzija za injekciju u napunjenoj štrcaljki, četverovalentno cjepivo protiv influence (fragmentirani virion, inaktivirano)
sanofi pasteur, 14 espace henry vallee, lyon, francuska - soj virusa influence (inaktivirani, fragmentirani) tip a (h1n1) soj virusa influence (inaktivirani, fragmentirani) tip a (h3n2) soj virusa influence (inaktivirani, fragmentirani) tip b - suspenzija za injekciju u napunjenoj štrcaljki - 1 doza = 0,5 ml - urbroj: jedna doza (0,5 ml) sadrži 15 mikrograma hemaglutinina po soju virusa influence (inaktivirani, fragmentirani) za sezonu aktualnih sojeva, tip a (h1n1), tip a (h3n2) i dva soja tipa b
pan-peni g sodium 1m i.j. prašak za rastvor za injekciju/infuziju
"farmont m.p." d.o.o. za proizvodnju, promet i usluge, export-import danilovgrad - benzilpenicilin - prašak za rastvor za injekciju/infuziju - 1m i.j.
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresivi - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psorijatični arthritiscosentyx, odvojeno ili u kombinaciji sa metotreksatom (mtx), propisan za liječenje aktivnog psorijatični artritis kod odraslih pacijenata, kada je odgovor na prethodna bolest дорабатывая anti-reumatskih lijekovi (dmards) terapija je bila neadekvatna.. Аксиальный спондилоартрит (axspa)ankilozantni спондилоартрит (kao, радиографические osi спондилоартрит)cosentyx indiciran za liječenje aktivnog анкилозирующего спондилита kod odraslih, koji su adekvatno odgovorili na standardnu terapiju. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
cosentyx (▼) 150 mg/1 ml rastvor za injekciju u napunjenom penu
novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenom penu - 150 mg/1 ml - 1 ml rastvora za injekciju sadrži: 150 mg sekukinumaba
cosentyx (▼) 150 mg/1 ml rastvor za injekciju u napunjenom penu
novartis ba d.o.o. - sekukinumab - rastvor za injekciju u napunjenom penu - 150 mg/1 ml - 1 ml rastvora za injekciju sadrži: 150 mg sekukinumaba